Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

G&A expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily due to lower iloperidone pre-commercial launch expenses. The decrease in G&A expenses in the third quarter of 2008 relative to the third quarter of 2007 is primarily due to lower employee stock-based compensation expense and lower iloperidone pre-commercial launch expenses.

-- Employee stock-based compensation expense recorded in the third quarter of 2008 totaled $3.6 million. Of these non-cash charges, $0.5 million was recorded as R&D expense and $3.1 million was recorded as G&A expense. In the second quarter of 2008 and the third quarter of 2007, total stock-based compensation was $4.0 million and $5.2 million, respectively. The decrease in stock-based compensation in the third quarter of 2008 relative to the second quarter of 2008 and the third quarter of 2007 is primarily due to the lower fair market value of options granted in 2008.

-- Net loss for the third quarter of 2008 was $10.9 million, compared to a net loss of $13.5 million for the second quarter of 2008 and $21.9 million for the third quarter of 2007.

-- Net loss per common share for the third quarter of 2008 was $0.41, compared to $0.51 for the second quarter of 2008 and $0.82 for the third quarter of 2007.

-- Cash and marketable securities decreased by $13.9 million during the third quarter of 2008. Changes included $10.9 million of net losses, decreases in accrued R&D expenses and accounts payable of $5.2 million, net increases in prepaid expenses of $0.9 million, fixed asset purchases of $0.5 million offset by $3.7 million in non-cash depreciation, amortization, and stock-based compensation expenses and net increases in other working capital of $0.1 million.

-- Vanda's cash, cash equivalents, and marketable securities as of September 30, 2008 totaled approximately $51.7 million, compared to approximately $93.2 million as of December 31, 2007.

FINANCIAL GUIDANCE '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... 2014 Vycom announces the addition of ... to meet Factory Mutual (FM) 4910 fire propagation and ... wet benches, process tools, fume hoods, furniture and cabinetry. ... to semiconductor wafers used in electronic chip manufacturing. ... solution with excellent workability and superior aesthetics. It is ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... FREMONT, Calif., Aug. 13 WaferGen Biosystems,Inc. (OTC ... expression, genotyping, cell biology and stem cell research ... and,announced financial results for the quarter and six ... Developments and Milestones:, -- Initiation of alpha ...
... MS, EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2008. BioMS Medical, in partnership with Eli Lilly ... for the treatment of MS,undergoing pivotal trials in ...
... Calif., Aug. 12 ChromaDex,Corporation, (OTC Bulletin Board: ... research, today announced financial results for the,second quarter ... accordance with,U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex ... $0.03 per share for the,three months ended June ...
Cached Biology Technology:WaferGen Announces Second Quarter 2008 Financial Results 2WaferGen Announces Second Quarter 2008 Financial Results 3WaferGen Announces Second Quarter 2008 Financial Results 4WaferGen Announces Second Quarter 2008 Financial Results 5WaferGen Announces Second Quarter 2008 Financial Results 6WaferGen Announces Second Quarter 2008 Financial Results 7WaferGen Announces Second Quarter 2008 Financial Results 8BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3
(Date:7/30/2014)... DCToday scientists unveiled the first high-resolution map of ... entire country of Per. The new and improved ... sea change for future market-based carbon economies. ... high ecological diversity and it provides the critical ... for conservation, land use, and enforcement purposes. The ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... Wake Forest University Baptist Medical Center and three ... activates the spores in anthrax, the deadly bacterial ... "A key aspect of anthrax spore biology concerns ... becomes a reproductive, disease-causing bacterium," explained Al Claiborne, ...
... Software (IOS) today,announced the release of GeneLinker(TM) ... award-winning Gene Expression and Proteomics Analysis,Software products.,"The ... and analyzing,protein biomarker data, a high priority ... have integrated the Protein Biomarker Package into ...
... deliver the hoped-for knockout punch breakthrough against the defences ... antibiotic resistance. , Techniques such as genomic sequencing and ... of new antibiotic compounds easier and more productive. But ... upper hand ?and if three billion years of bacterial ...
Cached Biology News:Scientists seek answers on what activates deadly anthrax spores 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3Learning to fight an adversary that won't stay down 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
muscle actin (HUC1-1)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: